02 radhakrishnan acute renal failure update
DESCRIPTION
TRANSCRIPT
Acute Renal FailureAn Update
Jai Radhakrishnan, MD, MS, FASN, FACCAssociate Professor of Clinical Medicine
Columbia University
Objectives
Epidemiology of ARF
Diagnostic workup
Specific syndromes of ARF
Treatment and Prevention
ARF-Definitions Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group Crit Care. 2004 Aug;8(4):R204
Changes in mortality in patients with acute renal failure over 47 years
Ympa YP Am J Med. 2005 Aug;118(8):827-32.
Etiology of ARF
Pre-renal (hemodynamic)
Intra-Renal (parenchymal)
Post-renal (obstructive)
ARF: Pre-renal
Volume DepletionCardiacRedistributionHepatorenalsyndrome
NSAIDSACE-inhibitors
Prostaglandins Angiotensin-II
Hepatorenal Syndrome: Diagnostic Criteria
Hepatology. 1996 Jan;23(1):164-76
MAJOR CRITERIA: Chronic/Acute liver disease with advanced hepatic failure and portal hypertensionLow GFR (Creatinine>1.5mg/dL or CrCl<40ml/min)Absence of shock, bacterial infection, nephrotoxin, GI /renal fluid lossesNo sustained renal improvement after withdrawing diuretics and volume expansion (1.5 L NS)Proteinuria<500mg/d and renal usg without obstruction or parenchymal abnormality
MINOR CRITERIAUrine Volume <500ml/dayUrine Na <10meq/LUrine RBC<50/HPFSerum Na <130meq/L
100100
9090
8080
7070
6060
5050
4040
3030
2020
1010
00--1414 --1313 --1212 --1111 --1010 --99 --88 --77 --66 --55
Agonist (Log M)Agonist (Log M)
Edwards AJP 1989Edwards AJP 1989
AVPAVPNENE
100100
9090
8080
7070
6060
5050
4040
3030
2020
1010
00--1414 --1313 --1212 --1111 --1010 --99 --88 --77 --66 --55
Agonist (Log M)Agonist (Log M)
AVPAVPNENE
% R
educ
tion
in L
umen
Dia
met
er%
Red
uctio
n in
Lum
en D
iam
eter
Efferent and Afferent Arterioles of Rabbit
Efferent Afferent
Terlipressin +/- Albumin In HRS
Hepatology 36 (2002), pp. 941–948
Hepatorenal Syndrome Type I: Vasopressin in One Patient
120120
100100
8080
6060
4040
2020
00
120120
100100
8080
6060
4040
2020
00--66 --44 --22 00 22 44 66 88
SBP SBP (mm Hg)(mm Hg)
Time (hrs)Time (hrs)
AVPAVP
SPASPA
SBP SBP (mm Hg)(mm Hg)
UOUO(cc/h)(cc/h)
UOUO(cc/h)(cc/h)
Diclofenac Residues as the Cause of Vulture population Decline in Pakistan
Nature. 2004 Feb 12;427(6975):
ARF: Post-renal
Consider obstruction in every patient with ARF.Sites of obstruction leading to ARF:
Bladder neck obstructionBilateral ureters
Urine volume variable.Renal USG or Bladder catheterization.
ARF: Intra-Renal
VASCULARVascular occlusionAtheroembolicdiseaseThrombotic microangiopathy
INTERSTITIALInterstitial nephritis
GLOMERULARAcute/Rapidly progressive glomerulonephritis
TUBULARCrystal ATN
Atheroembolic disease
ARF precipitated by angiographyOften eosinophilia and low complementMulti-organ dysfunction, livedo reticularis, blue toesGenerally irreversible
Acute Interstitial Nephritis
Triad of fever, skin rash and eosinophiliaEosinophiluriaDrugs: penicillin, cephalosporins, diuretics, NSAIDS, dilantinUsually completely reversible upon withdrawing drug?Glucocorticoids
Rapidly Progressive Glomerulonephritis
ETIOLOGYImmune complex GN: -post infectious,SLE, IgAN, SBE, cryoglobulinemiaAnti GBM antibody diseaseVasculitis: -Wegener’s, microscopic PAN, idiopathic crescentic GN
DIAGNOSTIC CLUESSystemic findingsSignificant proteinuria, RBC, RBC casts
Crystal-induced ARF
Uric acid (tumor-lysis)Oxalate (ethylene glycol)MethotrexateAcyclovirSulfonamidesIndinavirPhospho Soda
Uric Acid
Oxalate
Indinavir- Urine Crystals
Gagnon RF.. Am J Kidney Dis 2000 Sep;36(3):507-515
Osmotic Nephrosis
SucroseMannitolIntravenous immunoglobulinRadiocontrast agents
DextranHydroxyethyl starch
Ebcioglu Z.. Kidney International (2006) 70, 1873–1876.
J Am Soc Nephrol. 2005 Nov;16(11):3389-96.
Etiology of ATN
IschemicAll pre-renal causes
Exogenous ToxinsAntibioticsContrastChemotherapyOrg. solvents, Heavy metals
Endogenous Toxins
HemoglobinMyoglobinLight chains
Radiocontrast NephropathyClinical Course:
Onset of oliguria within 24 hoursPeak creatinine in 4-5 days followed by recovery in the majorityDifferential diagnosis: atheroembolic disease
Risk factors: AgeChronic kidney disease esp. diabetesPre-renal azotemia (e.g. cirrhosis, CHF)Volume of contrast
Contrast Nephropathy RiskS Creatinine> 0.5 mg/dl or > 25%at 48-72 h
Mehran R.. J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9.
Heme Pigment Induced ATN
Rhabdomyolysis: traumatic or non-traumaticIntravascular hemolysisMechanism uncertain: Vasoconstriction, precipitation/obstruction, toxicity of other breakdown productsConcomitant volume depletion
Aminoglycoside NephrotoxicityNon-oliguric renal failureOnset several days after treatmentRecovery is usually complete within 3 weeks
Mingeot-Leclercq MP… Antimicrob Agents Chemother. 1999 May;43(5):1003-12.
Top 5 Causes of ARF
Am J Kidney Dis. 2002 May;39(5):930-6
Urinary Indices in Oliguric ARF
*UNa / PNa ÷ UCr / PCr
Urinary Index Pre-renal ATN
Osmolality (mOsom/kg)
>500 <400
Sodium (meq/L) <20 >40
Fractional ex of Na <1 % >2%
Urine Microscopy
Red Cell Cast WBC Cast
Muddy (granular) Cast Broad Cast
Workup of Renal Failure
Post-Renal
Glomerular Vascular Interstitial Tubular
Renal Pre-Renal
Acute or Chronic
RENAL FAILURE
History, Physical, Urine analysis, USG
Treatment of ATN-2005
SUPPORTIVE CARE• Acid-base/electrolyte balance• Fluid balance• Nutrition• Review of drugs• Dialysis:
• PD, HD, Continuous modalities
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury.
N Engl J Med. 2008 May 20. [Epub ahead of print]
35 ml/kg/h
20 ml/kg/h
Course and Outcome of ATN
Am J Kidney Dis. 2002 May;39(5):930-6
Bruce A. Molitoris & Robert Bacallao
Pathogenesis of ATN
Tubuloglomerular feedback
EndothelinAdenosine
Nitric OxideProstacyclin
Source of ROS:XanthineDehydrogenaseNADH Oxidase
Pathogenesis of ATN: Reactive Oxygen Species
QUESTION: What preventive strategies have been consistently shown to be effective against ATN?
Maintaining euvolemia ?N-acetyl cysteine ?Dopamine ?Iso-osmolar contrast ?
Preventive StrategiesPOSITIVE:
HydrationEQUIVOCAL:
BicarbonateN-Acetyl CysteineTheophyllineIsoosmolar ContrastCRRT/Dialysis
NEGATIVE:Atrial natriuretic peptide Anti-endothelinantagonistFenoldopam
The Data
Effect on Mortality
Effect on need for Renal Replacement Therapy
Friedrich JO; Adhikari N; Herridge MS; Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death.Ann Intern Med 2005 Apr 5;142(7):510-24.
High-dose Furosemide for Established ARF
338 pts with ARF on dialysisFurosemide (25mg/kg IV or 35mg/kg PO, or matched placebo) daily.No difference in :
SurvivalRenal recovery
Shorter time to 2L/day diuresis
Am J Kidney Dis. 2004 Sep;44(3):402-9
Course and Outcome of ATN
Am J Kidney Dis. 2002 May;39(5):930-6
ARF Outcomes after Discharge: Survival979 pts who received CRRT69% in-hospital mortalityPost discharge survival:
6M: 89%5 Y: 50%
Morgera, S. American Journal of Kidney Disease 2002; 40(2):275-279
Morgera, S. American Journal of Kidney Disease 2002; 40(2):275-279
Korkeila, M. Nephrology, Dialysis, and Transplantation 2000
77% assessed health as “Good to excellent”69% resumed working57% self-sustainingMost Common Complaints:
Loss of energyDifficulty with heavy houseworkLimited physical mobility
ARF: Outcomes after DischargeQuality of Life
Future Developments
Biomarkers:Cell-based therapy
Current Status of Biomarkers
Neutrophil Gelatinase-associated Lipocalcin(NGAL)Kidney Injury Molecule-1Interleukin 18
Nickolas T.. Curr Opin Nephrol Hypertens. 2008 Mar;17(2):127-132
1514131211109876543210
25
50
75
100
125
150
175
200
225
2 4 6 8 12 24 36 48 60 72 84 96 108 120
Post CPB Time (hours)
Urin
e N
GAL
(ng/
ml)
No ARF(n=51)
ARF(n=20)
Serum Creat Rise
Urine NGAL is upregulated 15-fold within 2 hours after CPB in patients who later develop ARF
Lancet. 2005Apr;365(9466):1231-8.
2100
100
200
300
400
500
600
ARF(n=20)
No ARF(n=51)
Urin
e N
GAL
(ng/
ml)
2 hr
pos
t CPB
Urinary NGAL at 2 Hours Post CPB
50
The 2-hour urine NGAL was 50 ng/ml or higher in all patients who subsequently developed ARF
Lancet. 2005Apr;365(9466):1231-8.
Sensitivity: 100%Specificity: 98%PPV: 95%NPV: 100%
Ann Intern Med. 2008 Jun 3;148(11):810-9.
ConclusionsARF is common in hospitalized patients & has a high mortalityA significant number of patients recoverThe best (and least expensive) preventive strategy is to maintain euvolumia